Nasdaq:US$13.80 (+0.58) | HKEX:HK$21.50 (+0.25) | AIM:£2.11 (-0.05)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
>20
NOVEL DRUG CANDIDATES
CREATED BY IN-HOUSE
DISCOVERY ENGINE
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE US, EU & JAPAN
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
>150,000
PATIENTS TREATED BY
OUR NOVVEL MEDICINES

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


Corporate Presentation for Investors 2025-01-10
HUTCHMED Business Update Call 2025-01-07
UBS Greater China Conference 2025, Shanghai 2025-01-15